Efficient generation of bi- and tri-specific VHH next-generation biotherapeutics supported by a pipeline of developable VHHs.
Isogenica have developed fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific VHH and have exemplified this in in vitro studies.
- Isogenica’s libraries ensure standardised flanking sequences that can be easily slotted into bi- and tri-specific expression cassettes
- Cross-species specific anti-albumin VHH binds to protein A to simplify downstream CMC
- Production in mammalian expression systems and scaled-up purification facilitates developability and functional testing, including T-cell activation
VHH Antibody Pipeline
Isogenica are developing a suite of VHHs as stand alone assets and for incorporation into our multi-specific platform. Get in touch to accelerate your multi-specifics program.